Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ABT - Abbott Labs -- Ignore unavailable to you. Want to Upgrade?

To: Paul Nicholas who wrote (317)	9/21/2000 1:22:41 PM
From: Skywatcher	Respond to of 328

Finally getting the overdue increase in price over the 45 barrier...this one should hold with the new drug and overall I have a good feeling that since they are heavy into hospital supply biz, that area is going to get much stronger with the increase in payments from the government for medicare etc. They are not as dependent on just the prescription revenues as many of the other drug stocks... chris

To: Paul Nicholas who wrote (317)	9/21/2000 1:23:52 PM
From: Skywatcher	Respond to of 328

Finally getting the overdue increase in price over the 45 barrier...this one should hold with the new drug and overall I have a good feeling that since they are heavy into hospital supply biz, that area is going to get much stronger with the increase in payments from the government for medicare etc. They are not as dependent on just the prescription revenues as many of the other drug stocks... Todays' intraday chart looks FANTASTIC! chris

To: Paul Nicholas who wrote (317)	10/3/2000 9:17:27 AM
From: Skywatcher	Respond to of 328

Biocompatibles stent clears U.S. hurdle LONDON, Oct 3 (Reuters) - Medical devices company Biocompatibles International Plc said on Tuesday that the U.S. Food and Drug Administration had given pre-market approval (PMA) for its key stent product used to open arteries. The company received an approvable letter on its BiodivYsio stents from the FDA earlier this month. Crispin Simon, Chief Executive of Biocompatibles, said ``the PMA approval for our BiodivYsio stent is a major milestone for the company.'' The stents, tiny pieces of expandable steel tubing, are due to reach the U.S. market in 2001. Abbott Laboratories (NYSE:ABT - news) will distribute the product. More $$$...that's good chris

To: Paul Nicholas who wrote (317)	10/5/2000 12:36:16 PM
From: Skywatcher	Respond to of 328

Abbott Announces Five-Year Agreement with Consorta ABBOTT PARK, Ill., Oct. 5 /PRNewswire/ -- Abbott Laboratories (NYSE: ABT - news) today announced the signing of acontract with Consorta, Inc. for clinical chemistry and immunoassay laboratory testing kits and instruments. Abbott estimates sales to Consorta over the five-year agreement will exceed $250 million. The new agreement covers Abbott's clinical chemistry and immunoassay products including the Aeroset®, ARCHITECT® and AxSYM® diagnostic instrument systems. The five-year agreement begins November 1, 2000. ``We are excited about this contract award because it covers multiple product areas,'' said Thomas J. Heller, vice president, national accounts, Abbott Laboratories. ``Consorta has taken the lead in contracting for both clinical chemistry and immunoassay. This agreement allows Consorta members to maximize Abbott's full product offering, in turn realizing improved productivity and cost savings.'' Consorta, based in Rolling Meadows, Ill., is a group purchasing organization that represents more than half of the Catholic hospitals in the United States. Founded in 1998, Consorta has a collective annual purchase volume exceeding $2.5 billion. The Consorta membership encompasses more than 300 acute care facilities, representing nearly 50,000 beds, and 700 alternate care sites. ``Abbott has established a reputation as a leader in immunology and has a strong presence with our participants,'' said Darrel Weatherford, vice president of contracting for Consorta. ``This new agreement brings high quality, cost-effective product options and it is an important component of the Consorta portfolio for laboratory products.'' Abbott Laboratories is a global, diversified health care company devoted to the discovery, development, manufacture and marketing of pharmaceutical, diagnostic, nutritional and hospital products. The company employs 57,000 people and markets its products in more than 130 countries. In 1999, the company's sales and net earnings were $13.2 billion and $2.4 billion, respectively, with diluted earnings per share of $1.57. looking good chris

To: Paul Nicholas who wrote (317)	10/24/2000 1:57:16 PM
From: Skywatcher	Respond to of 328

No Genotypic Resistance Detected In Clinical Trials Through 48 and 108 Weeks With Abbott Laboratories' Kaletra(TM) (Lopinavir/Ritonavir) in Patients Without Previous HIV Therapy GLASGOW, Scotland, Oct. 24 /PRNewswire/ -- Data presented at the Fifth International Congress on Drug Therapy in HIV Infection in Glasgow show that to date, patients new to HIV therapy have not developed genotypic resistance to Abbott Laboratories' (NYSE: ABT - news) protease inhibitor (PI), Kaletra(TM) (lopinavir/ritonavir) (pronounced kuh-LEE-tra), even after 48 weeks of treatment in an ongoing Phase III clinical trial, and in an ongoing, smaller, dose-ranging study with no comparator group through two years. These analyses, conducted across studies using Kaletra as part of a first-line antiviral regimen, indicate that Kaletra has not been associated with the development of resistance in patients new to HIV therapy. Genotypic testing examines a viral sample for specific mutations, or changes, in the virus that are known to cause resistance to certain drugs. Kaletra, formerly known as ABT-378/r, is indicated for the treatment of HIV infection in adults and children as young as six months in combination with other antiretroviral medications. Accelerated approval of Kaletra is based on the response of viral load (amount of virus in the blood) measurements and CD4 cell count, both surrogate markers, from a 24-week controlled Phase III clinical trial and additional smaller open-label studies of 72 weeks in duration. The 72-week studies were designed to evaluate different doses of Kaletra and had no comparator groups. At present, there are no results from controlled trials evaluating the effect of Kaletra on the progression of HIV. ``Although Kaletra resistance may be observed with longer study, the lack of genotypic resistance detected to date with Kaletra in clinical trials in patients new to therapy is promising,'' said Eugene Sun, M.D., head of antiviral development, at Abbott Laboratories. In an ongoing, international, multi-center, double-blind, randomized clinical trial of 653 patients new to HIV therapy, the Kaletra regimen was compared to a regimen containing Viracept® (nelfinavir), a widely-used protease inhibitor. In addition to the protease inhibitor, patients in each of the treatment groups also received two nucleoside reverse transcriptase inhibitors (3TC and d4T). In this study, 326 patients received the Kaletra regimen and 327 patients received the nelfinavir regimen. Drug Resistance Analyses at 24 or 48 Weeks Plasma viral isolates from all patients on treatment who had detectable HIV (>400 copies/mL) at either week 24 or 48 were analyzed for evidence of genotypic resistance. Of those, genotypic analysis results were available for 31 Kaletra patients and 64 nelfinavir patients. Viral resistance is one of the causes of viral rebound and subsequent treatment failure for people with HIV. Results from this analysis showed that none (0/31) of the patients on the Kaletra regimen and 31 percent (20/64) of patients on the nelfinavir regimen exhibited genotypic resistance. More in the article...excellent news...stock still acting in the defensive drug mode...ie...dow up...abt down... biz.yahoo.com chris